GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Defence Therapeutics DTC.CN · CAD

Health Care · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.36

+1.43%

Close of 6 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2024

Net income

−C$13.2m

FY2019FY2024

Free cash flow

−C$4.5m

FY2019FY2024

Shareholders' equity

−C$3.6m

FY2019FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Research and developmentC$3.9mC$3.6mC$3.8mC$1.2mC$433,451—
Operating income−C$12.8m−C$6.5m−C$7.3m−C$2.9m−C$673,182−C$2,000
Net income−C$13.2m−C$6.8m−C$7.3m−C$2.9m−C$673,182−C$2,000
Diluted earnings per share-0.29-0.15-0.20-0.08-0.02-0.00

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsC$477,747C$3.5mC$719,666C$5.6mC$1.9mC$7,800
Cash and short-term investments—————C$800
Total liabilitiesC$4.1mC$2.0mC$1.1mC$122,256C$48,351C$7,800
Debt—C$1.7m————
Shareholders' equity−C$3.6mC$1.6m−C$387,558C$5.5mC$1.9m−C$100
Shares outstanding46m44m37m35m35m35m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−C$4.3m−C$7.7m−C$6.0m−C$2.3m−C$132,829−C$3,200
Capital spending−C$203,239−C$65,803——−C$46,018—
Free cash flow−C$4.5m−C$7.7m−C$6.0m−C$2.3m−C$178,847−C$3,200

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Operating income−C$1.4m−C$1.4m−C$606,581−C$1.0m−C$627,497−C$508,672−C$1.2m−C$1.2m
Net income−C$3.0m−C$1.5m−C$702,996−C$1.3m−C$804,837−C$606,862−C$1.3m−C$1.3m
Diluted earnings per share-0.04-0.03-0.01-0.02-0.02-0.01-0.03-0.03
Cash from operations−C$1.0m−C$1.0m—−C$1.0m———−C$2.0m
Total assetsC$9.4mC$1.4mC$2.8mC$2.4mC$403,028C$424,674C$477,747C$968,280
DebtC$1.6mC$1.5m——————
Shareholders' equityC$5.4m−C$1.2m−C$1.4m−C$219,723−C$3.5m−C$4.1m−C$3.6m−C$2.3m

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021
Price to earnings-2.3-15.1-13.0-39.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.